BRCA1 and neoplasm: MSH2, XRCC5, and BRCA1 tumor immunostaining assays were technically possible for 356 (77.2%), 396 (85.9%), and 221 (47.9%) patients with no complete histological response, respectively (Figure 1), revealing specific nuclear staining on a slide containing substantial tumor content, without extensive necrosis (Figure 2).